Search Results
72 Results Found for “PI3K/AKT pathway inhibitor ”
Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential ...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1 Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
Among glial tumours of the central nervous system (CNS), one of the most devastating is the category of H3K27-altered midline gliomas because of their uniform and rapid mortality, high neurological symptom burden and predilection for paediatric, adolescent and ...
As we begin 2026, Dr Ana Tecic Vuger (University Hospital for Tumors, Zagreb, Croatia) reflects on the major breakthroughs throughout 2025. The breast cancer community has witnessed transformative progress across the continuum of research and clinical care, from more precise targeted therapies and novel endocrine strategies to advances in biomarker-driven treatment sequencing and survivorship. The major oncology meetings – ASCO 2025, ESMO/ESMO Breast 2025, and the San Antonio Breast Cancer Symposium (SABCS) 2025 – offered a rich tapestry of data that helps shape practice and sharpen research priorities.
Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The ...
The phase III CAPItello-290 trial assessed the combination of capivasertib (C) with paclitaxel (P) as a first-line treatment for metastatic triple-negative breast cancer compared to paclitaxel plus placebo. A total of 812 patients were enrolled, with 30.7% showing PIK3CA/AKT1/PTEN ...
Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (...
Gastro-oesophageal cancers (GEC), which include both gastric (GC) and oesophageal cancers (EC), are among the most common cancers globally.1 In the USA, the American Cancer Society estimated 20,640 new diagnoses of EC and 26,380 new diagnoses of GC, each contributing to 16,410 and 11,090 ...
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1 CCAs tend to metastasize and have early lymph node ...
B-cell signalling pathways are critical regulators of B-cell development, expansion, and survival and function via various mediators, including Src family kinases (SFKs), spleen tyrosine kinase, Bruton’s tyrosine kinase (BTK) and phosphatidylinositol 3 kinase (PI3K) (Figure 1).1,2 BTK, a member of ...
Current treatment landscape in Canada Waldenström’s macroglobulinaemia (WM) is a rare haematological disorder with an incidence of about three cases per million, leading to approximately 150 new cases per year in Canada.1,2 WM is characterized by a clonal lymphoplasmacytic ...
Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has ...
Multiple myeloma is a plasma cell malignancy that typically develops in individuals in their late 60s with an average survival time of ~8 years.1 Despite recent advances in treatment, multiple myeloma remains largely incurable due to development of drug resistance in ...
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive ...
Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In ...
Human epidermal growth factor receptor 2 (HER2) is encoded by a proto-oncogene with important roles in the promotion of cell proliferation, differentiation and angiogenesis via the activation of Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) ...
Cholangiocarcinoma constitutes approximately 3% of all gastrointestinal malignancies, and the incidence is on the rise, especially the intrahepatic subtype. These tumors are anatomically broadly classified into intrahepatic, perihilar, and distal cholangiocarcinoma. Recent understanding of tumorigenesis pathways has shown that there exists ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
